{"transactions":[{"id":778297,"issuer":{"id":5808,"kind":"organization","name":"ABEONA THERAPEUTICS INC."},"owners":[{"id":47139,"kind":"person","name":"Crombez Eric","position":1,"cik":"0001653052","reported_name":"Crombez Eric","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-15T21:00:28.000Z","date":"2026-05-15","kind":"sale","planned":true,"acquired":false,"shares":26143,"price":5.5325,"value":144636.1475,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 4, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.44 to $5.66 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":37313,"source":{"system":"sec-edgar","filing":"0001493152-26-023912","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/318306/000149315226023912/ownership.xml","form_type":"4"}},{"id":789567,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":47139,"kind":"person","name":"Crombez Eric","position":1,"cik":"0001653052","reported_name":"Crombez Eric","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-05-06T18:51:11.000Z","date":"2026-05-05","kind":"sale","planned":false,"acquired":false,"shares":344,"price":24.96,"value":8586.24,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares sold to pay required tax withholdings due to the vesting of RSUs."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 558 shares acquired under the Company's Amended and Restated Employee Stock Purchase Plan on April 30, 2026"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions."}],"balance_after":111189,"source":{"system":"sec-edgar","filing":"0001193125-26-208632","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1515673/000119312526208632/ownership.xml","form_type":"4"}},{"id":804329,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":47139,"kind":"person","name":"Crombez Eric","position":1,"cik":"0001653052","reported_name":"Crombez Eric","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-20T21:11:06.000Z","date":"2026-04-16","kind":"grant","planned":false,"acquired":true,"shares":59952,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On the first anniversary of the grant date of the option (the \"Option Anniversary Date\"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date."}],"balance_after":59952,"derivative":{"exercise_price":24.52,"expiration_date":"2036-04-16","underlying":"Common Stock","underlying_shares":59952},"source":{"system":"sec-edgar","filing":"0001193125-26-164257","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1515673/000119312526164257/ownership.xml","form_type":"4"}},{"id":804328,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":47139,"kind":"person","name":"Crombez Eric","position":1,"cik":"0001653052","reported_name":"Crombez Eric","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-04-20T21:11:06.000Z","date":"2026-04-16","kind":"grant","planned":false,"acquired":true,"shares":34674,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Award of Restricted Stock Units (\"RSUs\") under the Company's 2023 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions."}],"balance_after":110975,"source":{"system":"sec-edgar","filing":"0001193125-26-164257","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1515673/000119312526164257/ownership.xml","form_type":"4"}},{"id":865568,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":47139,"kind":"person","name":"Crombez Eric","position":1,"cik":"0001653052","reported_name":"Crombez Eric","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-03-03T23:49:45.000Z","date":"2026-03-02","kind":"sale","planned":false,"acquired":false,"shares":7029,"price":22.8,"value":160261.2,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares sold to pay required tax withholdings due to the vesting of RSUs."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.54 to $23.11 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Includes 157 shares acquired on October 30, 2025 under the Company's Amended and Restated Employee Stock Purchase Plan"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions."}],"balance_after":76301,"source":{"system":"sec-edgar","filing":"0001193125-26-089104","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1515673/000119312526089104/ownership.xml","form_type":"4"}},{"id":865567,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":47139,"kind":"person","name":"Crombez Eric","position":1,"cik":"0001653052","reported_name":"Crombez Eric","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-03-03T23:49:45.000Z","date":"2026-03-01","kind":"grant","planned":false,"acquired":true,"shares":11643,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock which previously granted performance stock units were converted on March 1, 2026 upon certification of the performance metrics."}],"balance_after":83173,"source":{"system":"sec-edgar","filing":"0001193125-26-089104","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1515673/000119312526089104/ownership.xml","form_type":"4"}},{"id":926176,"issuer":{"id":5808,"kind":"organization","name":"ABEONA THERAPEUTICS INC."},"owners":[{"id":47139,"kind":"person","name":"Crombez Eric","position":1,"cik":"0001653052","reported_name":"Crombez Eric","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-02-02T23:55:32.000Z","date":"2026-02-02","kind":"sale","planned":false,"acquired":false,"shares":16284,"price":5.0906,"value":82895.3304,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was to cover tax obligations associated with the vesting of restricted stock awards."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.09 to $5.12 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":63456,"source":{"system":"sec-edgar","filing":"0001493152-26-004805","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/318306/000149315226004805/ownership.xml","form_type":"4"}},{"id":930629,"issuer":{"id":5808,"kind":"organization","name":"ABEONA THERAPEUTICS INC."},"owners":[{"id":47139,"kind":"person","name":"Crombez Eric","position":1,"cik":"0001653052","reported_name":"Crombez Eric","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-01-27T21:30:25.000Z","date":"2026-01-26","kind":"grant","planned":false,"acquired":true,"shares":37313,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"All of the restricted stock will vest on January 26, 2027."}],"balance_after":79740,"source":{"system":"sec-edgar","filing":"0001493152-26-003808","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/318306/000149315226003808/ownership.xml","form_type":"4"}},{"id":1065936,"issuer":{"id":5808,"kind":"organization","name":"ABEONA THERAPEUTICS INC."},"owners":[{"id":47139,"kind":"person","name":"Crombez Eric","position":1,"cik":"0001653052","reported_name":"Crombez Eric","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-08-15T20:30:30.000Z","date":"2025-08-14","kind":"sale","planned":false,"acquired":false,"shares":4718,"price":6.9273,"value":32683.0014,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was to cover tax obligations associated with the vesting of restricted stock awards."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.77 to $7.05 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":42427,"source":{"system":"sec-edgar","filing":"0001641172-25-024384","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/318306/000164117225024384/ownership.xml","form_type":"4"}},{"id":1158758,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":47139,"kind":"person","name":"Crombez Eric","position":1,"cik":"0001653052","reported_name":"Crombez Eric","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-05-05T23:18:48.000Z","date":"2025-05-05","kind":"sale","planned":false,"acquired":false,"shares":520,"price":39.24,"value":20404.8,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares sold to pay required tax withholdings due to the vesting of RSUs."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 370 shares acquired on April 30, 2025 under the Company's Amended and Restated Employee Stock Purchase Plan"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions."}],"balance_after":71530,"source":{"system":"sec-edgar","filing":"0000950170-25-063792","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1515673/000095017025063792/ownership.xml","form_type":"4"}},{"id":1158757,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":47139,"kind":"person","name":"Crombez Eric","position":1,"cik":"0001653052","reported_name":"Crombez Eric","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-05-05T23:18:48.000Z","date":"2025-04-21","kind":"sale","planned":false,"acquired":false,"shares":242,"price":35.11,"value":8496.62,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares sold to pay required tax withholdings due to the vesting of RSUs."}],"balance_after":71680,"source":{"system":"sec-edgar","filing":"0000950170-25-063792","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1515673/000095017025063792/ownership.xml","form_type":"4"}},{"id":1226916,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":47139,"kind":"person","name":"Crombez Eric","position":1,"cik":"0001653052","reported_name":"Crombez Eric","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Medical Officer"}}],"security":"Stock Ooption (Right to Buy)","published_at":"2025-03-05T01:16:48.000Z","date":"2025-03-01","kind":"grant","planned":false,"acquired":true,"shares":30246,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"On the first anniversary of the grant date of the option (the \"Option Anniversary Date\"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date."}],"balance_after":30246,"derivative":{"exercise_price":42.92,"expiration_date":"2035-03-01","underlying":"Common Stock","underlying_shares":30246},"source":{"system":"sec-edgar","filing":"0000950170-25-032794","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1515673/000095017025032794/ownership.xml","form_type":"4"}},{"id":1226915,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":47139,"kind":"person","name":"Crombez Eric","position":1,"cik":"0001653052","reported_name":"Crombez Eric","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-03-05T01:16:48.000Z","date":"2025-03-03","kind":"sale","planned":false,"acquired":false,"shares":8945,"price":42.1,"value":376584.5,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents shares sold to pay required tax withholdings due to the vesting of RSUs."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.77 to $42.90 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F6","text":"Includes 652 shares acquired on April 30, 2024 and October 31, 2024 under the Company's Amended and Restated Employee Stock Purchase Plan"}],"balance_after":71922,"source":{"system":"sec-edgar","filing":"0000950170-25-032794","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1515673/000095017025032794/ownership.xml","form_type":"4"}},{"id":1226914,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":47139,"kind":"person","name":"Crombez Eric","position":1,"cik":"0001653052","reported_name":"Crombez Eric","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-03-05T01:16:48.000Z","date":"2025-03-01","kind":"grant","planned":false,"acquired":true,"shares":14971,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares of common stock which previously granted performance stock units were converted on March 1, 2025 upon certification of the performance metric."}],"balance_after":80215,"source":{"system":"sec-edgar","filing":"0000950170-25-032794","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1515673/000095017025032794/ownership.xml","form_type":"4"}},{"id":1226913,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":47139,"kind":"person","name":"Crombez Eric","position":1,"cik":"0001653052","reported_name":"Crombez Eric","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-03-05T01:16:48.000Z","date":"2025-03-01","kind":"grant","planned":false,"acquired":true,"shares":16813,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Award of Restricted Stock Units (\"RSUs\") under the Company's 2023 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date"}],"balance_after":65244,"source":{"system":"sec-edgar","filing":"0000950170-25-032794","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1515673/000095017025032794/ownership.xml","form_type":"4"}},{"id":1288477,"issuer":{"id":5808,"kind":"organization","name":"ABEONA THERAPEUTICS INC."},"owners":[{"id":47139,"kind":"person","name":"Crombez Eric","position":1,"cik":"0001653052","reported_name":"Crombez Eric","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-02-04T01:37:39.000Z","date":"2025-01-31","kind":"grant","planned":false,"acquired":true,"shares":36101,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Upon vesting, a portion of the restricted stock may be surrendered to satisfy the reporting person's tax withholding obligation. Any deemed disposition of the withheld shares would be exempt pursuant to Rule 16b-3(e)."},{"field":"shares","element":"transactionShares","label":"F2","text":"All of the restricted stock will vest on January 31, 2026."}],"balance_after":47145,"source":{"system":"sec-edgar","filing":"0001493152-25-004753","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/318306/000149315225004753/ownership.xml","form_type":"4"}},{"id":1434287,"issuer":{"id":5808,"kind":"organization","name":"ABEONA THERAPEUTICS INC."},"owners":[{"id":47139,"kind":"person","name":"Crombez Eric","position":1,"cik":"0001653052","reported_name":"Crombez Eric","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-08-14T21:10:27.000Z","date":"2024-08-13","kind":"grant","planned":false,"acquired":true,"shares":11044,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Upon vesting, a portion of the restricted stock may be surrendered to satisfy the reporting person's tax withholding obligation. Any deemed disposition of the withheld shares would be exempt pursuant to Rule 16b-3(e)."},{"field":"shares","element":"transactionShares","label":"F2","text":"All of the restricted stock will vest on August 13, 2025."}],"balance_after":11044,"source":{"system":"sec-edgar","filing":"0001493152-24-032395","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/318306/000149315224032395/ownership.xml","form_type":"4"}},{"id":1527561,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":47139,"kind":"person","name":"Crombez Eric","position":1,"cik":"0001653052","reported_name":"Crombez Eric","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Medical Officer"}}],"security":"Common Stock","published_at":"2024-05-03T19:23:35.000Z","date":"2024-05-02","kind":"sale","planned":false,"acquired":false,"shares":354,"price":43.66,"value":15455.64,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares sold to pay required tax withholdings due to the vesting of RSUs."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions."}],"balance_after":48431,"source":{"system":"sec-edgar","filing":"0000950170-24-052788","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1515673/000095017024052788/ownership.xml","form_type":"4"}},{"id":1538280,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":47139,"kind":"person","name":"Crombez Eric","position":1,"cik":"0001653052","reported_name":"Crombez Eric","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Medical Officer"}}],"security":"Common Stock","published_at":"2024-04-19T20:35:51.000Z","date":"2024-04-18","kind":"sale","planned":false,"acquired":false,"shares":142,"price":44.1,"value":6262.2,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares sold to pay required tax withholdings due to the vesting of RSUs."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions."}],"balance_after":48785,"source":{"system":"sec-edgar","filing":"0000950170-24-046055","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1515673/000095017024046055/ownership.xml","form_type":"4"}},{"id":1594519,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":47139,"kind":"person","name":"Crombez Eric","position":1,"cik":"0001653052","reported_name":"Crombez Eric","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-03-06T01:10:42.000Z","date":"2024-03-01","kind":"grant","planned":false,"acquired":true,"shares":2351,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"On March 1, 2022, the Reporting Person was granted an option to purchase 2,351 shares of common stock. The option vests upon the achievement of specified performance criteria. Upon achievement of the performance criteria, 1/3 of the option vests on the date of certification by the Issuer's compensation committee of achievement of the performance criteria, 1/3 of the option vests on March 1, 2024 and 1/3 of the option vests on March 1, 2025. On March 1, 2024, the Issuer's compensation committee certified achievement of the performance criteria for the option, resulting in the vesting of the option of 1,568 shares on that date."}],"balance_after":2351,"derivative":{"exercise_price":67.37,"expiration_date":"2027-03-01","underlying":"Common Stock","underlying_shares":2351},"source":{"system":"sec-edgar","filing":"0000950170-24-026635","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1515673/000095017024026635/ownership.xml","form_type":"4"}},{"id":1594518,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":47139,"kind":"person","name":"Crombez Eric","position":1,"cik":"0001653052","reported_name":"Crombez Eric","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-03-06T01:10:42.000Z","date":"2024-03-01","kind":"grant","planned":false,"acquired":true,"shares":34200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"On the first anniversary of the grant date of the option (the \"Option Anniversary Date\"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date."}],"balance_after":34200,"derivative":{"exercise_price":53.69,"expiration_date":"2034-03-01","underlying":"Common Stock","underlying_shares":34200},"source":{"system":"sec-edgar","filing":"0000950170-24-026635","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1515673/000095017024026635/ownership.xml","form_type":"4"}},{"id":1594517,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":47139,"kind":"person","name":"Crombez Eric","position":1,"cik":"0001653052","reported_name":"Crombez Eric","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Medical Officer"}}],"security":"Common Stock","published_at":"2024-03-06T01:10:42.000Z","date":"2024-03-01","kind":"sale","planned":false,"acquired":false,"shares":1238,"price":53.76,"value":66554.88,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares sold to pay required tax withholdings due to the vesting of RSUs."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 253 shares acquired under the Company's Amended and Restated Employee Stock Purchase Plan on October 31, 2023."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions."}],"balance_after":48927,"source":{"system":"sec-edgar","filing":"0000950170-24-026635","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1515673/000095017024026635/ownership.xml","form_type":"4"}},{"id":1594516,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":47139,"kind":"person","name":"Crombez Eric","position":1,"cik":"0001653052","reported_name":"Crombez Eric","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Medical Officer"}}],"security":"Common Stock","published_at":"2024-03-06T01:10:42.000Z","date":"2024-03-01","kind":"grant","planned":false,"acquired":true,"shares":19400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Award of Restricted Stock Units (\"RSUs\") under the Company's 2023 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date"}],"balance_after":49912,"source":{"system":"sec-edgar","filing":"0000950170-24-026635","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1515673/000095017024026635/ownership.xml","form_type":"4"}},{"id":1771410,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":47139,"kind":"person","name":"Crombez Eric","position":1,"cik":"0001653052","reported_name":"Crombez Eric","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-09-29T18:15:35.000Z","date":"2023-09-27","kind":"grant","planned":false,"acquired":true,"shares":2351,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On March 1, 2022, the Reporting Person was granted an option to purchase 2,351 shares of common stock. The option vests upon the achievement of specified performance criteria.  Upon achievement of the performance criteria,  1/3 of the option vests on the date of certification by the Issuer's compensation committee of achievement of the performance criteria, 1/3 of the option vests on March 1, 2024 and 1/3 of the option vests on March 1, 2025. On September 27, 2023, the Issuer's compensation committee certified achievement of the performance criteria for the option, resulting in the vesting of the option of 784 shares on that date."}],"balance_after":2351,"derivative":{"exercise_price":67.37,"expiration_date":"2027-03-01","underlying":"Common Stock","underlying_shares":2351},"source":{"system":"sec-edgar","filing":"0001209191-23-050840","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1515673/000120919123050840/doc4.xml","form_type":"4"}},{"id":1907985,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":47139,"kind":"person","name":"Crombez Eric","position":1,"cik":"0001653052","reported_name":"Crombez Eric","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-05-02T22:18:31.000Z","date":"2023-05-01","kind":"grant","planned":false,"acquired":true,"shares":8362,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option shall vest with respect to 1/4th of the shares on the first anniversary of the grant date of the option and 1/48th of the shares initially subject to the option shall continue to vest on each month such that the option will fully vest on the fourth anniversary of the grant date."}],"balance_after":8362,"derivative":{"exercise_price":44.03,"expiration_date":"2033-05-01","underlying":"Common Stock","underlying_shares":8362},"source":{"system":"sec-edgar","filing":"0001209191-23-026692","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1515673/000120919123026692/doc4.xml","form_type":"4"}},{"id":1907984,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":47139,"kind":"person","name":"Crombez Eric","position":1,"cik":"0001653052","reported_name":"Crombez Eric","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Medical Officer"}}],"security":"Common Stock","published_at":"2023-05-02T22:18:31.000Z","date":"2023-05-01","kind":"grant","planned":false,"acquired":true,"shares":4658,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Award of Restricted Stock Units (\"RSUs\") under the Company's 2014 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions."}],"balance_after":30512,"source":{"system":"sec-edgar","filing":"0001209191-23-026692","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1515673/000120919123026692/doc4.xml","form_type":"4"}},{"id":4169895,"issuer":{"id":172012,"kind":"organization","name":"Dimension Therapeutics, Inc.","symbol":"DMTX"},"owners":[{"id":47139,"kind":"person","name":"Crombez Eric","position":1,"cik":"0001653052","reported_name":"Crombez Eric","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2017-11-07T17:05:21.000Z","date":"2017-11-07","kind":"disposition_to_issuer","acquired":false,"shares":50000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"This stock option, which vests in 48 equal monthly installments beginning January 18, 2017, was assumed by Ultragenyx and converted in accordance with the exchange ratio as set forth in the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This stock option, which vests in 48 equal monthly installments beginning January 18, 2017, was assumed by Ultragenyx and converted in accordance with the exchange ratio as set forth in the Merger Agreement."}],"balance_after":0,"derivative":{"exercise_price":1.9,"expiration_date":"2027-01-31","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001209191-17-059624","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1592288/000120919117059624/doc4.xml","form_type":"4"}},{"id":4169894,"issuer":{"id":172012,"kind":"organization","name":"Dimension Therapeutics, Inc.","symbol":"DMTX"},"owners":[{"id":47139,"kind":"person","name":"Crombez Eric","position":1,"cik":"0001653052","reported_name":"Crombez Eric","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2017-11-07T17:05:21.000Z","date":"2017-11-07","kind":"disposition_to_issuer","acquired":false,"shares":50000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This stock option, which vests in 48 equal monthly installments beginning January 27, 2016, was assumed by Ultragenyx and converted in accordance with the exchange ratio as set forth in the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This stock option, which vests in 48 equal monthly installments beginning January 27, 2016, was assumed by Ultragenyx and converted in accordance with the exchange ratio as set forth in the Merger Agreement."}],"balance_after":0,"derivative":{"exercise_price":7.14,"expiration_date":"2026-01-31","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001209191-17-059624","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1592288/000120919117059624/doc4.xml","form_type":"4"}},{"id":4169893,"issuer":{"id":172012,"kind":"organization","name":"Dimension Therapeutics, Inc.","symbol":"DMTX"},"owners":[{"id":47139,"kind":"person","name":"Crombez Eric","position":1,"cik":"0001653052","reported_name":"Crombez Eric","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2017-11-07T17:05:21.000Z","date":"2017-11-07","kind":"disposition_to_issuer","acquired":false,"shares":80396,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This stock option, which vested 8,375 shares on December 1, 2015, and vests in 43 equal monthly installments thereafter, beginning December 3, 2015, was assumed by Ultragenyx and converted in accordance with the exchange ratio as set forth in the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option, which vested 8,375 shares on December 1, 2015, and vests in 43 equal monthly installments thereafter, beginning December 3, 2015, was assumed by Ultragenyx and converted in accordance with the exchange ratio as set forth in the Merger Agreement."}],"balance_after":0,"derivative":{"exercise_price":4.09,"expiration_date":"2025-06-02","underlying":"Common Stock","underlying_shares":80396},"source":{"system":"sec-edgar","filing":"0001209191-17-059624","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1592288/000120919117059624/doc4.xml","form_type":"4"}},{"id":4169892,"issuer":{"id":172012,"kind":"organization","name":"Dimension Therapeutics, Inc.","symbol":"DMTX"},"owners":[{"id":47139,"kind":"person","name":"Crombez Eric","position":1,"cik":"0001653052","reported_name":"Crombez Eric","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2017-11-07T17:05:21.000Z","date":"2017-11-07","kind":"disposition_to_issuer","acquired":false,"shares":128292,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This stock option, which vests over four years beginning December 1, 2014, at a rate of 25% on December 17, 2015, and in 36 equal monthly installments thereafter, was assumed by Ultragenyx Pharmaceutical Inc. (\"Ultragenyx\"), and converted in accordance with the exchange ratio as set forth in the Agreement and Plan of Merger (the \"Merger Agreement\"), dated October 2, 2017, between the Issuer, Ultragenyx and Mystic River Merger Sub Inc., a direct, wholly-owned subsidiary of Ultragenyx."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option, which vests over four years beginning December 1, 2014, at a rate of 25% on December 17, 2015, and in 36 equal monthly installments thereafter, was assumed by Ultragenyx Pharmaceutical Inc. (\"Ultragenyx\"), and converted in accordance with the exchange ratio as set forth in the Agreement and Plan of Merger (the \"Merger Agreement\"), dated October 2, 2017, between the Issuer, Ultragenyx and Mystic River Merger Sub Inc., a direct, wholly-owned subsidiary of Ultragenyx."}],"balance_after":0,"derivative":{"exercise_price":0.56,"expiration_date":"2024-12-16","underlying":"Common Stock","underlying_shares":128292},"source":{"system":"sec-edgar","filing":"0001209191-17-059624","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1592288/000120919117059624/doc4.xml","form_type":"4"}},{"id":4467832,"issuer":{"id":172012,"kind":"organization","name":"Dimension Therapeutics, Inc.","symbol":"DMTX"},"owners":[{"id":47139,"kind":"person","name":"Crombez Eric","position":1,"cik":"0001653052","reported_name":"Crombez Eric","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2017-02-03T16:40:22.000Z","date":"2017-02-01","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option vests in forty-eight (48) equal monthly installments beginning on January 18, 2017."}],"balance_after":50000,"derivative":{"exercise_price":1.9,"expiration_date":"2027-01-31","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001209191-17-007652","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1592288/000120919117007652/doc4.xml","form_type":"4"}}]}